Intra-Cellular Therapies (ITCI) Financial Analysis & Valuation | Quarter Chart
Intra-Cellular Therapies (ITCI)
ITCIPrice: $131.87
Fair Value: 🔒
🔒score
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schi... more
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment ... more
Description
Shares
| Market Cap | $14.05B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | US | CEO | Sharon Mates |
| IPO Date | 2014-01-07 | CAGR | 0.63% |
| Employees | 860 | Website | www.intracellulartherapies.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ITCI chart loading...
Fundamentals
Technicals
| Enterprise Value | $8.32B | P/E Ratio | -180.64 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 26.22 | P/B Ratio | 11.84 |
| P/CF Ratio | -348.17 | P/FCF Ratio | -356.68 |
| EPS | $-0.73 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 47.27% | Gross Margin | 0.91% |
| Operating Margin | -0.18% | Profit Margin | -0.11% |
| ROE | -0.05% | ROA | -0.04% |
| ROCE | -0.08% | Current Ratio | 6.36 |
| Quick Ratio | 6.23 | Cash Ratio | 1.49 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 38.03 | Piotroski Score | 2 |